上海中医药大学研究生导师信息表
姓
名
出生年月
刘平
性 别
男
民
族
汉
1953.8
学 历
研究生
学
位
博士
技术职称
教授、研究员
导
类
师
别
二级学院
曙光医院/肝病研究所
职
务
从事专业
中医内科学
研究方向
博士生导师
专业
代码
100506
中医药防治慢性肝病的临床与基础研究
[1] Zhou Y. N., Sun M. Y., Mu Y. P., Yang T., Ning B. B., Ren S., Chen J. M., Liu P.
Xuefuzhuyu decoction inhibition of angiogenesis attenuates liver fibrosis induced by
CCl(4) in mice[J]. J Ethnopharmacol,2014,153(3):659-666.
[2] Wang Xiaoning, Xie Guoxiang, Wang Xiaoyan, Zhou Mingmei, Yu Huan, Lin Yan, Du
Guangli, Luo Guoan, Liu Ping. Urinary Metabolite Profiling Offers Potential for
Differentiation of Liver-Kidney Yin Deficiency and Dampness-Heat Internal Smoldering
Syndromes in Post-Hepatitis B Cirrhosis Patients[J]. Evidence-Based Complementary and
Alternative
Medicine,2014,vol.
2014,
Article
ID
464969,
11
pages,
2014.
doi:10.1155/2014/464969.
[3] Zhang L. J.，Sun M. Y.，Ning B. B.，Zhang W. M.，Chen G. F.，Mu Y. P.，Zhang H.，
Liu J.，Bian Y. Q.，Liu P. Xiayuxue Decoction (下淤血汤) attenuates hepatic stellate cell
activation and sinusoidal endothelium defenestration in CCl4-induced fibrotic liver of
mice[J]. Chin J Integr Med,2014,20(7):516-523.
[4] Li Qing-Ya, Guo Zhi-Zhong, Deng Xin, Xu Lie-Ming, Gao Yue-Qiu, Zhang Wei,
Wang Xiao-Su, Xue Dong-Ying, Lu Yi-Yu, Liu Ping, Su Shi-Bing. Curative Effects of
近五年研究
成果
ZHENG-Based Fuzheng-Huayu Tablet on Hepatitis B Caused Cirrhosis Related to
CYP1A2 Genetic Polymorphism[J]. Evidence-Based Complementary and Alternative
Medicine,2013,2013:7.
[5] Yin X., Peng J., Zhao L., Yu Y., Zhang X., Liu P., Feng Q., Hu Y., Pang X. Structural
changes of gut microbiota in a rat non-alcoholic fatty liver disease model treated with a
Chinese herbal formula[J]. Syst Appl Microbiol,2013,36(3):188-196.
[6] Jiang P., Shi R., Wang Q., Ma Y. M., Cui H. Y., Liu P., Liu C. H. Simultaneous
determination of eleven major components in Fugan Fang using high-performance liquid
chromatography
coupled
with
mass
spectrometry[J].
Biomed
Chromatogr,2013,27(7):874-881.
[7] Deng Yan-Ru, Ma Hong-Di, Tsuneyama Koichi, Yang Wei, Wang Yin-Hu, Lu
Fang-Ting, Liu Cheng-Hai, Liu Ping, He Xiao-Song, Diehl Anna Mae, Gershwin M. Eric,
Lian Zhe-Xiong. STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the
protein kinase inhibitor sorafenib[J]. Journal of Autoimmunity,2013,46:25-34.
[8] Gou X., Tao Q., Feng Q., Peng J., Zhao Y., Dai J., Wang W., Zhang Y., Hu Y., Liu P.
Urine metabolic profile changes of CCl4-liver fibrosis in rats and intervention effects of Yi
Guan Jian Decoction using metabonomic approach[J]. BMC Complement Altern
Med,2013,13:123.
[9] Gou X., Tao Q., Feng Q., Peng J., Sun S., Cao H., Zheng N., Zhang Y., Hu Y., Liu P.
Urinary metabonomics characterization of liver fibrosis induced by CCl(4) in rats and
intervention effects of Xia Yu Xue Decoction[J]. J Pharm Biomed Anal,2013,74:62-65.
[10] Liu P. Fuzheng huayu capsule in the treatment of liver fibrosis: clinical evidence and
mechanism of action[J]. Chin J Integr Med,2012,18(5):398-400.
[11] Wang Xiaoning, Wang Xiaoyan, Xie Guoxiang, Zhou Mingmei, Yu Huan, Lin Yan,
Du Guangli, Luo Guoan, Jia Wei, Liu Ping. Urinary Metabolite Variation is Associated
with Pathological Progression of the Post-Hepatitis B Cirrhosis Patients[J]. J Proteome
Res,2012,11(7):3838-3847.
[12] Zhang H., Lv H., Huang P. X., Lin Y., Hu X. C., Liu P. Comparative Study of TCM
Syndrome Scale for Liver Disease and Chronic Liver Disease Questionnaire Based on
Assessment
of
Posthepatitic
Cirrhosis[J].
Evid
Based
Complement
Alternat
Med,2012,2012:496575.
[13] Du J. X., Sun M. Y., Du G. L., Li F. H., Liu C., Mu Y. P., Chen G. F., Long A. H.,
Bian Y. Q., Liu J., Liu C. H., Hu Y. Y., Xu L. M., Liu P. Ingredients of Huangqi decoction
slow biliary fibrosis progression by inhibiting
the activation of the transforming growth
factor-beta signaling pathway[J]. BMC Complement Altern Med,2012,12(1):1-11.
[14] Zhang H., Li Q. Y., Guo Z. Z., Guan Y., Du J, Lu Y. Y., Hu Y. Y., Liu P., Huang S.,
Su S. B. Serum levels of microRNAs can specifically predict liver injury of chronic
hepatitis B[J]. World J Gastroenterol,2012,18(37):5188-5196.
[15] Sun M., Cao H., Sun L., Dong S., Bian Y., Han J., Zhang L., Ren S., Hu Y., Liu C.,
Xu L., Liu P. Antitumor activities of kushen: literature review[J]. Evid Based Complement
Alternat Med,2012,2012:373219.
[16] Wang X. L., Jia D. W., Liu H. Y., Yan X. F., Ye T. J., Hu X. D., Li B. Q., Chen Y. L.,
Liu P. Effect of Yiguanjian decoction on cell differentiation and proliferation in
CCl(4)-treated mice[J]. World J Gastroenterol,2012,18(25):3235-3249.
[17] Liu C., Wang G., Chen G., Mu Y., Zhang L., Hu X., Sun M., Liu C., Liu P. Huangqi
decoction inhibits apoptosis and fibrosis, but promotes Kupffer cell activation in
dimethylnitrosamine-induced
rat
liver
fibrosis[J].
BMC
Complement
Altern
Med,2012,12:51.
[18] Yao C., Tang N., Xie G., Zheng X., Liu P., Fu L., Xie W., Yao F., Li H., Jia W.
Management of hepatic encephalopathy by traditional chinese medicine[J]. Evid Based
Complement Alternat Med,2012,2012:835686.
[19] Liu P. Modern research of TCM etiology and pathogenesis theory and translational
medicine[J]. Journal of Translational Medicine,2012,10(Suppl 2):A36.
[20] Chen Yue-Lei, Lv Jing, Ye Xiao-Lei, Sun Ming-Yu, Xu Qin, Liu Cheng-Hai, Min
Li-Hua, Li Hui-Ping, Liu Ping, Ding Xiaoyan. Sorafenib inhibits transforming growth
factor β 1-Mediated Epithelial-Mesenchymal Transition and apoptosis in mouse
hepatocytes[J]. Hepatology,2011,53(5):1708-1718.
[21] Fu W. W., Fu J. N., Zhang W. M., Sun L. X., Pei Y. H., Liu P. Platycoside O, a new
triterpenoid
saponin
from
the
roots
of
Platycodon
grandiflorum[J].
Molecules,2011,16(6):4371-4378.
[22] Fu Wen-Wei, Tan Chang-Heng, Zhuang Peng-Yu, Yang Shu-Min, Luo Hong-Feng,
Tan Jun-Jie, Liu Ping, Zhu Da-Yuan. Purinium Derivatives with Antitumor Activities from
Heterostemma alatum Wight[J]. Heterocycles,2011,6(83):1405-1408.
[23] Zhang W. M., Fu W. W., Sun M. Y., Sun L. X., Jia Y. R., Liu P. Simultaneous
determination of five nucleosides and nucleobases of Rehmannia glutinosa Libosch. by
high performance liquid chromatography[J]. Yao Xue Xue Bao,2011,46(11):1380-1384.
[24] Chen T., Xie G., Wang X., Fan J., Qiu Y., Zheng X., Qi X., Cao Y., Su M., Wang X.,
Xu L. X., Yen Y., Liu P., Jia W. Serum and urine metabolite profiling reveals potential
biomarkers
of
human
hepatocellular
carcinoma[J].
Mol
Cell
Proteomics,2011,10(7):M110-M4945.
[25] Liu C., Tao Q., Sun M., Wu J. Z., Yang W., Jian P., Peng J., Hu Y., Liu C., Liu P.
Kupffer cells are associated with apoptosis, inflammation and fibrotic effects in hepatic
fibrosis in rats[J]. Lab Invest,2010,90(12):1805-1816.
[26] Hu X. D., Jiang S. L., Liu C. H., Hu Y. Y., Liu C., Sun M. Y., Chen G. F., Liu P.
Preventive effects of 1,25-(OH)2VD3 against ConA-induced mouse hepatitis through
promoting
vitamin
D
receptor
gene
expression[J].
Acta
Pharmacol
Sin,2010,31(6):703-708.
*请按课题名称、课题级别及来源、课题经费**万元填写
目前在研课
题
招生
类别
扶正化瘀片抗肝纤维化的美国Ⅲ期临床试验前研究，国家科技重大专项
（重大新药创制），1400 万元
基于 Smad7 蛋白表达调控解析黄芪总皂苷与甘草酸配伍抗肝纤维化的
效应机制，国家自然科学基金面上项目，75 万元
扶正化瘀方抗肝纤维化作用机制的网络药理学及其关键技术研究，上海
市科委，60 万元
茵陈蒿汤片创新药物的临床研究，国家科技部重大新药专项，400 万元
学生
类别
博士生/硕士生
学位类别
科学学位